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Abstract
Background: Diacylglycerol kinase (DGK) is an enzyme that phosphorylates diacylglycerol to produce phosphatidic acid.
DGKb is one of the subtypes of the DGK family and regulates many intracellular signaling pathways in the central nervous
system. Previously, we demonstrated that DGKb knockout (KO) mice showed various dysfunctions of higher brain function,
such as cognitive impairment (with lower spine density), hyperactivity, reduced anxiety, and careless behavior. In the
present study, we conducted further tests on DGKb KO mice in order to investigate the function of DGKb in the central
nervous system, especially in the pathophysiology of attention deficit hyperactivity disorder (ADHD).
Methodology/Principal Findings: DGKb KO mice showed attention-deficit behavior in the object-based attention test and
it was ameliorated by methylphenidate (MPH, 30 mg/kg, i.p.). In the open field test, DGKb KO mice displayed a decreased
response to the locomotor stimulating effects of MPH (30 mg/kg, i.p.), but showed a similar response to an N-methyl-D-
aspartate (NMDA) receptor antagonist, MK-801 (0.3 mg/kg, i.p.), when compared to WT mice. Examination of the
phosphorylation of extracellular signal-regulated kinase (ERK), which is involved in regulation of locomotor activity,
indicated that ERK1/2 activation induced by MPH treatment was defective in the striatum of DGKb KO mice.
Conclusions/Significance: These findings suggest that DGKb KO mice showed attention-deficit and hyperactive phenotype,
similar to ADHD. Furthermore, the hyporesponsiveness of DGKb KO mice to MPH was due to dysregulation of ERK
phosphorylation, and that DGKb has a pivotal involvement in ERK regulation in the striatum.
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Introduction
Stimulation of cell surface Gq protein-coupled receptors by
many extracellular stimuli such as growth factors, hormones, and
neurotransmitters, activates phospholipase C and results in the
production of diacylglycerol (DG) from inositol phospholipids [1].
DG then directly binds to protein kinase C, activating this
multifunctional enzyme [2]. DG also activates other proteins such
as Ras guanyl nucleotide-releasing proteins [3]. DG is further
converted to phosphatidic acid (PA), and PA in turn also activates
many other proteins, such as mammalian target of rapamycin and
Raf-1 kinase [4]. The conversion of DG to PA is catalyzed by
diacylglycerol kinase (DGK) [5]; that is, DGK controls the
functional balance of these two lipid mediators by catabolizing DG
and producing PA.
To date, ten DGK isozymes have been identified from
mammalian cells [6,7,8]. Among these, DGKb is classified as a
type I DGK, as it possesses a calcium-binding EF-hand [9].
DGKb is widely distributed in the brain, particularly in the
olfactory bulb, cerebral cortex, striatum, and hippocampus, all of
which are areas that correspond to the dopaminergic projection
field [10]. In addition, coexpression of DGKb with dopamine D1
and D2 receptors has been reported in medium spiny neurons of
the striatum, suggesting a connection between DGKb and
dopaminergic transmission [11].
Dysfunction in dopamine signaling has been implicated in many
neuropsychiatric disorders, such as Parkinson’s disease, schizo-
phrenia, attention deficit hyperactivity disorder (ADHD), and drug
abuse. Analysis of the human DGKb gene has demonstrated that a
splice variant at the COOH-terminal of DGKb is related to
bipolar disorder [12]. Related to this, we have reported that
DGKb knockout (KO) mice show mania-like behavior which is
attenuated by lithium treatment [13]. We and other researchers
have also reported that spine formation was regulated by the
control of lipid levels by DGKb and that DGKb KO mice showed
impaired memory [14,15]. These findings suggest that DGKb is
directly involved in the regulation of psychomotor behavior and
higher brain functions.
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ized by inattention, impulsivity, and hyperactivity. It had been
reported that a majority of children, adolescents, and adults with
ADHD are affected by other comorbid psychiatric conditions,
such as bipolar disorders [16,17]. We made a hypothesis that
DGKb which is suspected of contributing to bipolar disorder, also
plays some important roles in ADHD.
Methylphenidate (MPH) is a psychostimulant drug approved for
treatment of ADHD, postural orthostatic tachycardia syndrome,
and narcolepsy. Some reports have indicated that MPH treatment
significantly decreases the hyperactive locomotor activity of mice
with dopamine transporter KO [18], casein kinase Id overexpres-
sion [19], or p35 KO [20].
In the present study, we further analyzed the behavior of DGKb
KO mice using some behavioral tests and a psychostimulant MPH
in order to investigate the function of DGKb in the central
nervous system, especially in the pathophysiology of ADHD.
Materials and Methods
Animals
DGKb KO mice (C57BL/6N) were generated using the Sleeping
Beauty transposon system as described in our previous report [14].
Wild-type (WT) and DGKb KO mice were generated by breeding
heterozyrous mutants, and we used WT littermates as a control
group of DGKb KO mice. The animals (8–20 weeks old) were
housed at 2462uC under a 12 hrs light-dark cycle (lights on from
8:00 to 20:00) and had ad libitum to food and water. These studies
were approved by the Animal Experiment Committee of Gifu
Pharmaceutical University (permission number; 2009-061, 2009-
331, 2009-378, 2010-396, 2010-398, 2011-067, 2011-083, 2011-
283, and 2011-416). All procedures relating to animal care and
treatment conformed to the animal care guidelines of this
committee. All efforts were made to minimize both suffering and
the number of animals used. Only aged-matched male mice were
used for behavioral experiments, and all other tests included age-
matched males and females in proportional contribution across
groups. Behavioral experiments were performed during the light
phase, between 10:00 and 18:00. To avoid stress-interference in
the behavioral tests, mice were not repeatedly used.
Object-based attention test
The experiment were performed based on a previous report
[21]. The apparatus is a rectangular, two-chambered boxes
including exploring chamber (length 306width 306height 22 cm)
and test chamber (length 306width 156height 22 cm). The
chambers were always bedded with fresh animal bedding for every
mouse after the floors of chambers were wiped with tissue paper
(70% alcohol). The experiments were divided into three different
phases: a habituation phase, an acquisition phase, and a retention
phase. On the habituation phase, mice were individually subjected
to a single familiarization session of 10 min, during which they
were exposed to both empty chambers. On the acquisition phase,
animals were subjected to a single 3-min or 6-min session, during
which five objects (A, B, C, D, and E) were placed separately in the
exploring chamber. All objects were made of the same wooden
material with the similar color and smell, but different in shape.
On the retention phase, one of the object in the exploring chamber
(object B) was placed into the test chamber in parallel with the
novel F object, which was also made of the same wooden material
with the similar color and smell, but different in shape with other
objects. Then the mouse was immediately allowed to enter the test
chamber (within 10 s) and to explore two objects (object B and F)
for 3 min. For the analysis, all sessions were recorded using video
camera, and the time spent exploring each object was measured
using stopwatch. A recognition index of retention session was
expressed as the ratio (TF6100)/(TB+TF), where TB and TF are
the time spent on object B and object F, respectively.
To evaluate the effect of MPH on the attention, vehicle (saline)
or MPH (30 mg/kg) was intraperitoneally injected (i.p.) 20 min
before habituation phase.
Open field test
For the assessment of the rearing behavior in the novel
environment, each mouse was placed in the periphery of the
open field apparatus (length 306width 306height 30 cm), and
mouse behavior was monitored for 5 min. The number of rearing
actions was counted manually.
For measurement of the effects of psychostimulants on
locomotor activity, each mouse was placed in the open field
apparatus. Thirty minutes later, MPH (0.3, 3, or 30 mg/kg), MK-
801 (0.3 mg/kg), or vehicle (saline) was injected (i.p.), the mouse
was returned to the apparatus, and monitored for a further 90 min
after injection. The total distance moved in the arena was
recorded using a computer-operated EthoVision XT system
(Noldus, Wageningen, the Netherlands). Stereotypies and rearing
were analyzed manually by an observer blind to the treatment for
5 min. Stereotype behaviors were defined as sniffing while
immobile, grooming, licking the bottom of wall of the box. The
total duration of stereotyped behaviors and the number of rearing
were analyzed.
Catalepsy test
Time spent in a cataleptic position was monitored by
positioning the mouse so that both front paws rested on a
0.3 cm diameter pole 3.5 cm above a bench surface. The time for
which each mouse maintained this position was recorded up to a
maximum of 2 min. Haloperidol (Sigma Aldrich, St. Louis, MO,
USA) dissolved in 0.3% tartaric acid was administered i.p. and
catalepsy was measured 1 h after haloperidol administration, and
three times in each test session.
Immunostaining
Mice were anesthetized with sodium pentobarbital (50 mg/kg,
i.p.) (Nembutal; Dainippon-Sumitomo Pharmaceutical Co. Ltd.,
Osaka, Japan) and brains were perfusion-fixed with 4% parafor-
maldehyde (Wako Pure Chemical Industries, Osaka, Japan) in
0.1 M phosphate buffer (pH 7.4). The brains were removed after a
20-min perfusion fixation at 4uC, then immersed in the same
fixative solution overnight at 4uC. The brains were then immersed
in 25% sucrose (Wako) in 0.1 M phosphate buffer for 24 h, and
frozen. Coronal brain sections (14 mm) were cut on a cryostat and
placed on slides (MASCOAT; Matsunami, Osaka, Japan). The
sections were washed for 5 min in 0.01 M phosphate buffered
saline (PBS), then treated with 0.3% hydrogen peroxidase (Wako)
in 10% methanol (Wako). They were then washed three times in
0.01 M PBS, followed by a 30-min pre-incubation with 10%
normal goat serum. The sections were then incubated with anti-
tyrosine hydroxylase (TH) antibody (1:200 dilution; Millipore,
Billerica, MA, USA), including 0.3% triton X-100 (Nacalai tesque,
Kyoto, Japan), for 3 h at 4uC. After a 15-min rinse in changes of
0.01 M PBS, the sections were incubated with biotinylated second
rabbit antibody for 2 h, and then with an avidin-biotin peroxidase
complex (ABC Elite kit; Vector Laboratories, Peterborough, UK)
for 30 min (both at room temperature). Optical density measure-
ments of striatal TH immunostaining were obtained by digital
image analysis (Scion, Frederick, MD, USA).
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Each mouse was decapitated and the brain was quickly
removed from the skull, briefly washed in ice-cold saline, and
laid on a cooled (4uC) metal plate, on which the brain was
rapidly dissected to separate the striatum, hippocampus, and
prefrontal cortex. To extract protein, the tissue was homogenized
in cell-lysis buffer using a homogenizer (Physcotron; Microtec
Co. Ltd., Chiba, Japan). The lysate was centrifuged at 12,0006g
for 20 min and the supernatant used for this study. The protein
concentration was measured by comparison with a known
concentration of bovine serum albumin using a BCA Protein
Assay Kit (Pierce Biotechnology, Rockford, IL, USA). A mixture
of equal parts of an aliquot of protein and sample buffer with
10% 2-mercaptoethanol was subjected to 10% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis. The separated protein
was then transferred onto a polyvinylidene difluoride membrane
(Immobilon-P; Millipore). For immunoblotting, the following
primary antibodies were used: Monoclonal Anti-D1 Dopamine
Receptor antibody (1:500 dilution; Sigma Aldrich), Anti-Dopa-
mine D2 Receptor (1:1000 dilution; Millipore), Phospho-p44/42
MAPK (Erk1/2) (Thr202/Tyr204) (197G2) Rabbit mAb, p44/42
MAPK (Erk1/2) Rabbit pAb, anti-GAPDH Rabbit mAb (1:1000
dilution; Cell signaling, Danvers, MA, USA), and monoclonal
anti-b-actin (1:5000 dilution; Sigma Aldrich). The secondary
antibody was as follows: HRP-conjugated goat anti-mouse IgG,
HRP-conjugated goat anti-rabbit IgG (1:2000 dilution; Pierce
Biotechnology). Immunoreactive bands were visualized using
Immuno StarH LD (Wako). The band intensity was measured
using a LUMINESCENT IMAGE ANALYZER LAS-4000 UV
mini (Fujifilm, Tokyo, Japan) and Multi Gauge Ver. 3.0
(Fujifilm). The protein levels of total or phosphorylated ERK1/
2 were analyzed at the same time. For a quantitative analysis,
total proteins were used as loading controls for phosphoprotein
signals.
Statistical analysis
Data are presented as mean 6 standard error of the mean
(S.E.M.). Statistical comparisons were made by Student’s t-test,
chi-square test, or one-way ANOVA followed by Dunnett’s test
using JSTAT software (Vector, Tokyo, Japan). Two-way ANOVA
followed by post hoc one-way ANOVA with Bonferroni’s multiple
comparison test was used in analyzing data. Probability (p) values
of less than 5% were considered statistically significant.
Results
DGKb KO mice exhibited attention-deficit behaviors
To evaluate the attention-deficit behavior of DGKb KO mice,
we performed the object-based attention test, in accordance with
previous report [21]. Firstly, mice were exposed to the five objects
for 3 min (training session) and then, after an interval of 10 s, they
were exposed to two objects that include a familiar and a novel
objects for 3 min (retention session) (Figure 1A). There were no
changes in the exploration time on each object during the training
session (Figure 1B). In retention session, WT mice spent more time
on the novel object, while DGKb KO mice spent less time on the
novel object (Figure 1C). But, when mice were exposed to the five
objects for 6 min in training session (Figure 1D), in which WT and
DGKb KO mice spent equal time on each objects (Figure 1E),
there was no difference in the time spent in the novel object during
retention session (Figure 1F). In all retention sessions, WT and
DGKb KO mice spent equal time on exploring two objects
(Figure S1). These results suggest that DGKb KO mice showed
attention-deficit behavior.
The effect of methylphenidate (MPH) on the attention of
DGKb KO mice
Deficit of attention is a distinctive symptom of ADHD and
ameliorated somewhat by therapeutic medicines such as MPH.
To investigate whether attention-deficit behavior of DGKb KO
mice were ameliorated by MPH, we performed object-based
attention test after MPH treatment. Throughout the experiment,
MPH treatment decreased the time spent on exploring each
objects (Figure S1E and F). In the WT mice, MPH treatment
significantly decreased the recognition index, suggesting the
attention-deficit behavior. On the other hand, MPH treatment
significantly increased the recognition index of DGKb KO mice
(Figure 1G).
These results suggest that MPH improved the inattention of
DGKb KO mice.
DGKb KO mice were hyporesponsive to methylphenidate
(MPH)-induced behavioral change
It is well known that MPH increase extracellular levels of
dopamine, leading to an enhancement of locomotor activity in
normal animals [22]. We administered various doses of MPH
and investigated the change of locomotor activity for 90 min.
Compared vehicle-treated WT mice with DGKb KO mice, the
locomotor activity of DGKb KO mice was significantly
increased. MPH increased the locomotor activity in WT mice,
and it was significant at 3 and 30 mg/kg (i.p., MPH 0.3 mg/kg;
p=0.318, MPH 3 mg/kg; p=0.005, and MPH 30 mg/kg;
p=0.003 vs. vehicle-treated WT mice). On the other hands,
MPH did not increase the locomotor activity in DGKb KO mice
(MPH 0.3 mg/kg; p=1.000, MPH 3 mg/kg; p=0.958, and
MPH 30 mg/kg; p=1.000 vs. vehicle-treated KO mice)
(Figure 2A). We also assessed the changes over time after
MPH (30 mg/kg, i.p.) treatment. Administration of MPH to WT
mice resulted in a marked increase in locomotor activity,
followed by transient decrease (Figure 2B). Compared to the
WT mice, in the DGKb KO mice, MPH slightly increased the
locomotor activity soon after MPH treatment (at the point of
35 min) (Figure 2C). We found significant effects of genotype
[F(1, 24)=9.01, p,0.01], treatment [F(1, 24)=31.69, p,0.001],
and genotype6treatment interaction [F(1, 24)=14.32, p,0.001].
In this study, we measured rearing behavior, another
stereotyped behavior in the novel environments. The number
of rearing behaviors was significantly increased in DGKb KO
mice compared to WT mice in the novel environment
(Figure 2D). The rearing behavior of vehicle-treated DGKb
KO mice remained higher than that of vehicle-treated WT mice
30 min after beginning experiment. MPH treatment significantly
reduced the rearing behavior of DGKb KO mice to an equal
number of vehicle-treated WT mice (Figure 2E). We also
investigated the duration of rearing behavior. They indicated a
similar tendency, but no significance (p=0.13) [WT (control):
11.4765.16 s WT (MPH): 3.4261.55 s KO (control):
38.5469.88 s KO (MPH): 3.9661.46 s]. Furthermore, we
investigated the duration of stereotyped behavior other than
rearing in the same time. The stereotyped behavior other than
rearing of vehicle-treated DGKb KO mice was less than that of
vehicle-treated WT mice, but the difference was not significant
(p=0.056). After MPH treatment, the stereotyped behavior of
WT mice was significantly reduced, but there were no changes in
the DGKb KO mice (Figure 2F). These results suggest that
DGKb KO mice showed low responsiveness to MPH.
Not only the elevation of dopaminergic transmission, but also
pharmacological disruption of the glutamatergic transmission was
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assessed the psychostimulant effect of an N-methyl-D-aspartate
(NMDA) receptor antagonist, MK-801 (dizocilpine) with the same
method. In contrast to the case of MPH, locomotor activity in
response to MK-801 treatment increased equally in both WT and
DGKb KO mice (Figure 3A–C).
No changes occurred in dopaminergic neurons and
receptors
As DGKb KO mice showed abnormal behavioral change
against MPH, we hypothesized that changes in the dopamine
system might have occurred in the DGKb KO mice. In the
striatum, no difference was noted in the density of TH-
Figure 1. DGKb KO mice showed an attention-deficit behavior in object-based attention test. (A) Mice were exposed to five objects for
3 min (training session), then, after an interval of 10 s, they were exposed to two objects that include a familiar and a novel objects for 3 min
(retention session). (B) Object exploration time during the 3-min training session. (C) The novel-object discriminating abilities of mice were expressed
as a recognition index. Values are expressed as the mean 6 S.E.M. (KO: n=8, WT: n=9) *; p,0.01 vs. WT mice (t-test). (D) Mice were exposed to five
objects for 6 min (training session), then, after an interval of 10 sec, they were exposed to two objects that include a familiar and a novel objects for
3 min (retention session). (E) Object exploration time during the 6-min training session. (F) The novel-object discriminating abilities of mice were
expressed as a recognition index. Values are expressed as the mean 6 S.E.M. (KO: n=6, WT: n=7). (G) The effect of MPH on the recognition index in
retention phase after 3-min training phase. Values are expressed as the mean 6 S.E.M. (n=6, 7) *; p,0.05, **; p,0.01 vs. vehicle-treated WT mice, #;
p,0.05 vs. vehicle-treated KO mice (Tukey’s test).
doi:10.1371/journal.pone.0037058.g001
Behavioral Phenotype of DGKß KO Mice
PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e37058Figure 2. DGKb KO mice showed an abnormal response to methylphenidate. (A) The locomotor activity after various doses of MPH. Each
mouse was placed in a locomotor activity monitor for an initial period of 30 min and then injected with vehicle or MPH (0.3, 3, 30 mg/kg, i.p.).
Horizontal activities of 90 min after drug treatment were recorded. Values are expressed as the mean 6 S.E.M. (n=5) *; p,0.05 vs. vehicle-treated WT
mice (t-test), #;p ,0.05, ##;p ,0.01 vs. vehicle-treated WT mice (Dunnett’s test). Each mouse was placed in a locomotor activity monitor for an
initial period of 30 min (shown as arrow) and then injected with vehicle or MPH (30 mg/kg). Horizontal activity was recorded every 5 min for a 2-h
period. Locomotor activity throughout the 2-h period of WT (B) and DGKb KO (C) mice. Values are expressed as the mean 6 S.E.M. (n=4 to 10) *;
p,0.05, **; p,0.01 vs. vehicle-treated group (t-test). (D) Rearing behavior of WT and DGKb KO mice in the first 5 min of open field test. Values are
expressed as the mean6 S.E.M. (n=5, 7) *; p,0.05 vs. WT mice (t-test). (E) Rearing behavior of MPH/vehicle treated WT and KO mice for 5 min after
drug treatment. Values are expressed as the mean 6 S.E.M. (n=4 to 10) *; p,0.05, **; p,0.01 vs. vehicle-treated KO mice group (t-test). (F) The
duration of the stereotyped behaviors for 5 min after drug treatment. Values are expressed as the mean 6 S.E.M. (n=4 to 10) *; p,0.05, **; p,0.01
vs. vehicle-treated WT mice group (t-test).
doi:10.1371/journal.pone.0037058.g002
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(Figure 4A and B).
Previously, dysfunction of the dopamine D2 receptor has been
reported in some genetically-modified animal models that showed
lower responsiveness to methamphetamine-induced sensitization
[25]. For this reason, we investigated the function of the dopamine
D2 receptor, by measuring the degree of catalepsy induced by the
dopamine D2 antagonist, haloperidol. Again, no difference was
noted in the persistence time of catalepsy induced by haloperidol
between WT and DGKb KO mice (Figure 4E), suggesting that
DGKb KO mice had normal dopamine D2 receptor function.
Furthermore, no changes were found in the relative protein
expression of the dopamine D1 receptor or D2 receptor in the
striatum (Figure 4C and D).
The changes of phosphorylation levels of ERK1/2 after
methylphenidate treatment
Mouse locomotor behavior after psychostimulant treatment is
known to be correlated with the phosphorylation levels of ERK1/
2. For this reason, we also evaluated the phosphorylation level of
ERK1/2 in the striatum of DGKb KO mice. In the basal
condition, no changes were noted in the phosphorylation levels of
ERK1/2 in the striatum of DGKb KO mice (WT; 1.0060.04,
KO; 1.0260.12, n=6). In contrast, 5 min after MPH treatment,
Figure 3. DGKb KO mice showed normal responses to MK-801-induced hyperactivity. Each mouse was placed in a locomotor activity
monitor for an initial period of 30 min (shown as arrow) and then injected with vehicle or MK-801 (0.3 mg/kg). Horizontal activity was recorded every
5 min for a 2-h period. Locomotor activity throughout the 2-h period of WT (A) and DGKb KO (B) mice. Values are expressed as the mean 6 S.E.M.
(n=4 or 5) *; p,0.05, **; p,0.01. (C) Total horizontal activities of 90 min after drug treatment were recorded. Values are expressed as the mean 6
S.E.M. (n=4 or 5) *; p,0.05, **; p,0.01 vs. vehicle-treated WT mice (t-test), ##;p ,0.01 vs. vehicle-treated KO mice (t-test).
doi:10.1371/journal.pone.0037058.g003
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the WT mice, but not in DGKb KO mice (Figure 5A and B). The
levels of total ERK proteins were not changed by the MPH
treatment in either genotype.
Furthermore, we investigated the phosphorylation levels of
ERK1/2 in the hippocampus and prefrontal cortex at 5 min after
MPH treatment to investigate whether MPH also affects the
phosphorylation levels of ERK1/2 in these regions. In these
regions, MPH did not affect the phosphorylation levels of ERK1/
2 both in WT and KO mice (Figure S2). Previous report also
showed that MPH had no effect on the phosphorylation levels of
ERK1/2 in the prefrontal cortex [26]. These results suggest that
the effect of MPH might be mainly mediated in the striatum.
We further investigated the cAMP-dependent pathway, which
also plays a role in dopamine signaling. Five min after MPH
treatment, there were no changes in the phosphorylation levels of
GluR1 (Ser845) in the striatum of WT mice (data not shown). Forty
min after MPH treatment, the phosphorylation levels of GluR1
(Ser845) was significantly increased in the striatum of WT mice. In
the striatum of DGKb KO mice, there were also increases of the
phosphorylation levels of GluR1 (Ser845) (Figure 5C and D).
Discussion
The purpose of the present study was to evaluate DGKb KO
mice as an animal model of ADHD. ADHD is characterized by
Figure 4. Dopaminergic systems in the striatum of the DGKb KO mice. (A) Representative photograph of the coronal sections of the striatum
immunostained for tyrosine hydroxylase (TH) of WT and DGKb KO mice. Scale bar shows 300 mm. (B) Optical density of TH-positive fibers in the
striatum of WT and DGKb KO mice. Values are expressed as the mean 6 S.E.M. (n=3). (C) Representative immunoblots showing the expression levels
of D1 dopamine receptor (D1DR) and D2 dopamine receptor (D2DR) in the striatum of WT and DGKb KO mice. (D) Protein levels of D1DR and D2DR
are quantified relative to the GAPDH levels. Values are expressed as the mean 6 S.E.M. (n=6). (E) The retention time of haloperidol-induced catalepsy
of WT and DGKb KO mice. Values are expressed as the mean 6 S.E.M. (n=6 to 12).
doi:10.1371/journal.pone.0037058.g004
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revealed that DGKb KO mice showed attention-deficit like
behavior and hyperactive behavior which was especially pro-
nounced in the familiar environment than in the novel environ-
ment. With regard to hyperactivity, phenotype of DGKb KO
mice appears similar to that of ADHD patients and spontaneously
hypertensive rats [27]. In attention-deficit behavior of DGKb KO
mice, it was ameliorated by the MPH, which is commonly used as
a treatment of ADHD. The effects of MPH against the locomotor
activity of DGKb KO mice were not similar to those of ADHD
patients and general animal models of ADHD, other therapeutic
agents for ADHD might show improving effects in DGKb KO
mice. These findings might suggest some involvements of DGKb
in the pathophysiology of ADHD. Unfortunately, to our
knowledge, there is no report suggesting the mutations or
polymorphisms in the DGKb gene in ADHD patients. Further
studies will be needed to make clear the involvement of DGKb in
ADHD.
To date, several behavioral tests were established to evaluate the
animal attention. For example, in a 5-choice serial reaction time
task, detections of attentional deficits of animal require training the
subjects for long-term to enable them to acquire the behavioral
skills [28]. Object-based attention test detects the deficit of
attention of animals in a short time and usefulness of this test is
recognized in p-chlorophenylalanine- or phencyclidine-treated
mice [21]. Previously, we reported that hippocampally-based
memory is affected in DGKb KO mice [14]. Working memory
and attention have much in common and are much dependent
[21]. Therefore, there may be a possibility that hippocampal input
is partly involved in this result.
MPH is a psychostimulant drug that exerts its pharmacological
properties by blocking dopamine transporters and raising the
extracellular concentration of dopamine in various brain regions
[29]. MPH treatment was reported to cause significant decreases
in the hyperactive locomotor activity of mice with dopamine
transporter KO [18], casein kinase Id overexpression [19], or p35
KO [20]. In the present study, we used 30 mg/kg as the highest
dose, which induced transient decreasing of locomotor activity
after rapid increment in WT mice. This change over time of
locomotor activity was seen in previous report [18]. MPH
administration did not decrease locomotor activity of DGKb
KO mice, but the increment of locomotor activity was smaller
than that seen in WT mice. Considering that DGKb KO mice
showed a normal response to MK-801, the absence of DGKb did
not affect the psychomotor stimulant response to the non-
competitive NMDA receptor antagonist.
We also investigated the rearing behavior and other stereotyped
behavior. Stereotyped behavior, such as rearing behavior, has
been observed in a mouse model of psychiatric disorders [30]. In
this study, DGKb KO mice frequently showed rearing behavior.
In some animal models of ADHD, the increment of vertical
activities was also reported [19], therefore, increment of rearing
behavior of DGKb KO mice might be caused by its hyperactivity.
The effect of psychostimulants on stereotyped behaviors of animals
was reported by some researchers [31,32]. In this study, we
investigated stereotyped behaviors for a short time (5 min), and
MPH treatment decreased them in WT mice, but not in DGKb
KO mice. It might be due to the dramatically increment of
locomotor activity of WT mice in this time point.
Previously, three major striatal signaling pathways (protein
kinase A/DARPP-32 [33–34], Akt/glycogen synthase kinase 3
[35], and ERK [36–37]) were reported to regulate dopamine-
mediated locomotor activity. Of these, the ERK signaling in
particular appears to play an important, but as yet undetermined,
role in psychostimulant stimulus responses [18]. Under basal
conditions, no differences in the expression level or functions of
dopamine receptors were observed between WT and DGKb KO
mice. In addition, no changes were noted in the levels of ERK1/2
phosphorylation in the striatum when WT and DGKb KO mice
were compared. These results suggest that the hyperactive
phenotype of DGKb KO mice is not due to the dopaminergic
signal in the striatum. In the present study, we found no changes in
Figure 5. Western blot analysis of the phosphorylation levels
of ERK1/2 and GluR1 in the striatum. Phosphorylated and total
ERK1/2 levels in the striatum were measured by Western blot analysis.
(A) Representative immunoblots showing the expression levels of
phosphorylated ERK1/2 (p-ERK1/2) and total ERK1/2 (t-ERK1/2) in the
striatum of WT and DGKb KO mice 5 min after drug treatment. (B)
Phosphorylation levels of ERK1/2 are quantified relative to the t-ERK1/2
levels. Values are expressed as the mean 6 S.E.M. (n=5 to 8) **; p,0.01
v.s. vehicle-treated WT mice group (t-test). (C) Representative immu-
noblots showing the expression levels of phosphorylated GluR1 (p-
GluR1) in the striatum of WT and DGKb KO mice 40 min after drug
treatment. (D) Phosphorylation levels of GluR1 are quantified relative to
the b-actin levels. Values are expressed as the mean 6 S.E.M. (n=6 to 8)
*; p,0.01 vs. vehicle-treated WT mice group, ##;p ,0.01 vs. vehicle-
treated KO mice group (t-test).
doi:10.1371/journal.pone.0037058.g005
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following MPH treatment.
It has been reported that methylphenidate affects dopamine/
DARPP-32 signaling in adult [38]. Previous work has shown that,
in dopamine D1 receptor KO mice and Thr-34RAla DARPP-32
(T34A) mutant mice, no ERK activation occurred in the striatum
following d-amphetamine treatment [39], suggesting that dopa-
mine D1 receptor/DARPP-32 signal activate ERK following a
stimulus by a phychostimulant drug. DGKs, which convert DG to
PA, are located downstream of Gq-protein [5]. Dopamine D2
agonists are thought to activate ERK in striatal slices via coupling
of a Gq-protein to phospholipase C b pathway and mobilization of
intracellular calcium stores [40].
Although dopamine D1 and D2 receptors are classically
considered to be localized in distinct striatal subpopulations [41],
some reports suggests a synergism of both D1 and D2 receptors in
the same striatal subpopulation [37]. This would mean that both
dopamine D1 and D2 receptors are involved in ERK phosphor-
ylation and that DGKb regulates the ERK phosphorylation.
However, MPH also affect the norepinephrine transporters [42],
so, further study would need to examine the upstream factors of
ERK after MPH treatment.
Previously, it was reported that some DGK isozymes (a, f, and
i) influence the signaling of Ras, an upstream molecule of the B-
Raf/C-Raf/MEK (mitogen-activated protein kinase/extracellular
signal-regulated kinase kinas)/ERK pathway, by modulating
activities of Ras guanyl nucleotide-releasing protein [43–45].
Interestingly, it was revealed that DGKg regulates B-Raf/C-Raf/
MEK/ERK signaling cascade acting as scaffold/adaptor protein
[46]. Although the structure, expression pattern, and function of
DGKs were diverse and each has its own biological functions,
there is a possibility that DGKb also involved in the regulation of
B-Raf/C-Raf/MEK/ERK signaling cascade. However, further
studies are needed to clarify the detailed mechanism that underlies
DGKb regulation of ERK phosphorylation.
In conclusion, DGKb KO mice showed attention-deficit
behavior and abnormal response to MPH-induced hyperactivity.
These results suggest the involvement of DGKbin the pathophys-
iology of ADHD. Because DGKb is downstream signals of various
receptors, there is a possibility that various signaling is affected at
the same time. Further studies on the functions of DGKb may lead
to clarification of the mechanisms of many neurological diseases.
Supporting Information
Figure S1 The time spent exploring each objects in the
retention test of object-based attention test. (A) Object
exploration time during the retention test after 3-min training
session. (B) Total exploration time during the retention test after 3-
min training session. Values are expressed as the mean 6 S.E.M.
(KO: n=8, WT: n=9). (C) Object exploration time during the
retention test after 6-min training session. (D) Total exploration
time during the retention test after 6-min training session. Values
are expressed as the mean 6 S.E.M. (KO: n=6, WT: n=7). (E)
Object exploration time of vehicle or MPH treated mice during
the retention test after 3-min training session. (F) Total exploration
time of vehicle or MPH treated mice during the retention test after
3-min training session. Values are expressed as the mean 6
S.E.M. (n=6, 7) *; p,0.05 vs. vehicle-treated WT mice, #;
p,0.05 vs. vehicle-treated KO mice.
(TIFF)
Figure S2 Western blot analysis of the phosphorylation
levels of ERK1/2 in the prefrontal cortex and hippo-
campus. Phosphorylated and total ERK1/2 levels in the
prefrontal cortex were measured by Western blot analysis.
Representative immunoblots showing the expression levels of
phosphorylated ERK1/2 (p-ERK1/2) and total ERK1/2 (t-
ERK1/2) in the prefrontal cortex of WT and DGKb KO mice
5 min after (A) and 40 min (B) after drug treatment. Represen-
tative immunoblots showing the expression levels of phosphory-
lated ERK1/2 (p-ERK1/2) and total ERK1/2 (t-ERK1/2) in the
hippocampus of WT and DGKb KO mice 5 min after (C) and
40 min (D) after drug treatment. Values are expressed as the mean
6 S.E.M. (n=6).
(TIFF)
Author Contributions
Conceived and designed the experiments: MI K. Kakefuda AO KT MS
HH. Performed the experiments: MI K. Kakefuda YO K. Kitaichi.
Analyzed the data: MI K. Kakefuda. Contributed reagents/materials/
analysis tools: MI K. Kakefuda AO YO. Wrote the paper: MI.
References
1. Rhee SG, Bae YS (1997) Regulation of phosphoinositide-specific phospholipase
C isozymes. J Biol Chem 272: 15045–15048.
2. Nishizuka Y (1995) Protein kinase C and lipid signaling for sustained cellular
responses. Faseb J 9: 484–496.
3. Merida I, Avila-Flores A, Merino E (2008) Diacylglycerol kinases: at the hub of
cell signalling. Biochem J 409: 1–18.
4. Ghosh S, Strum JC, Sciorra VA, Daniel L, Bell RM (1996) Raf-1 kinase
possesses distinct binding domains for phosphatidylserine and phosphatidic acid.
Phosphatidic acid regulates the translocation of Raf-1 in 12-O-tetradecanoyl-
phorbol-13-acetate-stimulated Madin-Darby canine kidney cells. J Biol Chem
271: 8472–8480.
5. Kanoh H, Yamada K, Sakane F (1990) Diacylglycerol kinase: a key modulator
of signal transduction? Trends Biochem Sci 15: 47–50.
6. Topham MK (2006) Signaling roles of diacylglycerol kinases. J Cell Biochem 97:
474–484.
7. Goto K, Hozumi Y, Nakano T, Saino SS, Kondo H (2007) Cell biology and
pathophysiology of the diacylglycerol kinase family: morphological aspects in
tissues and organs. Int Rev Cytol 264: 25–63.
8. Sakane F, Imai S, Kai M, Yasuda S, Kanoh H (2007) Diacylglycerol kinases:
why so many of them? Biochim Biophys Acta 1771: 793–806.
9. Goto K, Kondo H (1999) Diacylglycerol kinase in the central nervous system–
molecular heterogeneity and gene expression. Chem Phys Lipids 98: 109–117.
10. Goto K, Kondo H (1993) Molecular cloning and expression of a 90-kDa
diacylglycerol kinase that predominantly localizes in neurons. Proc Natl Acad
Sci U S A 90: 7598–7602.
11. Hozumi Y, Fukaya M, Adachi N, Saito N, Otani K, et al. (2008) Diacylglycerol
kinase beta accumulates on the perisynaptic site of medium spiny neurons in the
striatum. Eur J Neurosci 28: 2409–2422.
12. Caricasole A, Bettini E, Sala C, Roncarati R, Kobayashi N, et al. (2002)
Molecular cloning and characterization of the human diacylglycerol kinase beta
(DGKbeta) gene: alternative splicing generates DGKbeta isotypes with different
properties. J Biol Chem 277: 4790–4796.
13. Kakefuda K, Oyagi A, Ishisaka M, Tsuruma K, Shimazawa M, et al. (2010)
Diacylglycerol kinase beta knockout mice exhibit lithium-sensitive behavioral
abnormalities. PLoS One 5: e13447.
14. Shirai Y, Kouzuki T, Kakefuda K, Moriguchi S, Oyagi A, et al. (2010) Essential
role of neuron-enriched diacylglycerol kinase (DGK), DGK beta in neurite spine
formation, contributing to cognitive function. PLoS One 5: e11602.
15. Hozumi Y, Watanabe M, Otani K, Goto K (2009) Diacylglycerol kinase beta
promotes dendritic outgrowth and spine maturation in developing hippocampal
neurons. BMC Neurosci 10: 99.
16. Reich W, Neuman RJ, Volk HE, Joyner CA, Todd RD (2005) Comorbidity
between ADHD and symptoms of bipolar disorder in a community sample of
children and adolescents. Twin Res Hum Genet 8: 459–466.
17. Nierenberg AA, Miyahara S, Spencer T, Wisniewski SR, Otto MW, et al. (2005)
Clinical and diagnostic implications of lifetime attention-deficit/hyperactivity
disorder comorbidity in adults with bipolar disorder: data from the first 1000
STEP-BD participants. Biol Psychiatry 57: 1467–1473.
Behavioral Phenotype of DGKß KO Mice
PLoS ONE | www.plosone.org 9 May 2012 | Volume 7 | Issue 5 | e3705818. Beaulieu JM, Sotnikova TD, Gainetdinov RR, Caron MG (2006) Paradoxical
striatal cellular signaling responses to psychostimulants in hyperactive mice.
J Biol Chem 281: 32072–32080.
19. Zhou M, Rebholz H, Brocia C, Warner-Schmidt JL, Fienberg AA, et al. (2010)
Forebrain overexpression of CK1delta leads to down-regulation of dopamine
receptors and altered locomotor activity reminiscent of ADHD. Proc Natl Acad
Sci U S A 107: 4401–4406.
20. Krapacher FA, Mlewski EC, Ferreras S, Pisano V, Paolorossi M, et al. (2010)
Mice lacking p35 display hyperactivity and paradoxical response to psycho-
stimulants. J Neurochem 114: 203–214.
21. Alkam T, Hiramatsu M, Mamiya T, Aoyama Y, Nitta A, et al. (2011) Evaluation
of object-based attention in mice. Behav Brain Res 220: 185–193.
22. Segal DS, Kuczenski R (1997) Repeated binge exposures to amphetamine and
methamphetamine: behavioral and neurochemical characterization. JPharmacol
Exp Ther 282: 561–573.
23. Carlsson M, Carlsson A (1989) The NMDA antagonist MK-801 causes marked
locomotor stimulation in monoamine-depleted mice. J Neural Transm 75:
221–226.
24. Gainetdinov RR, Mohn AR, Bohn LM, Caron MG (2001) Glutamatergic
modulation of hyperactivity in mice lacking the dopamine transporter. Proc Natl
Acad Sci U S A 98: 11047–11054.
25. Shioda N, Yamamoto Y, Watanabe M, Binas B, Owada Y, et al. (2009) Heart-
type fatty acid binding protein regulates dopamine D2 receptor function in
mouse brain. J Neurosci 30: 3146–3155.
26. Pascoli V, Valjent E, Corbille AG, Corvol JC, Tassin JP, et al. (2005) cAMP and
extracellular signal-regulated kinase signaling in response to d-amphetamine and
methylphenidate in the prefrontal cortex in vivo: role of beta 1-adrenoceptors.
Mol Pharmacol 68: 421–429.
27. Arime Y, Kubo Y, Sora I (2011) Animal models of attention-deficit/
hyperactivity disorder. Biol Pharm Bull 34: 1373–1376.
28. Bari A, Dalley JW, Robbins TW (2008) The application of the 5-choice serial
reaction time task for the assessment of visual attentional processes and impulse
control in rats. Nat Protoc 3: 759–767.
29. Volkow ND, Wang GJ, Fowler JS, Gatley SJ, Logan J, et al. (1998) Dopamine
transporter occupancies in the human brain induced by therapeutic doses of oral
methylphenidate. Am J Psychiatry 155: 1325–1331.
30. Verebey K, Kogan MJ, Mule SJ (1981) Phencyclidine-induced stereotype in rats:
effects of methadone, apomorphine, and naloxone. Psychopharmacology (Berl)
75: 44–47.
31. Kiguchi M, Fujita S, Oki H, Shimizu N, Cools AR, et al. (2008) Behavioural
characterisation of rats exposed neonatally to bisphenol-A: responses to a novel
environment and to methylphenidate challenge in a putative model of attention-
deficit hyperactivity disorder. J Neural Transm 115: 1079–1085.
32. Park SW, Shen X, Tien LT, Roman R, Ma T (2011) Methamphetamine-
induced changes in the striatal dopamine pathway in mu-opioid receptor
knockout mice. J Biomed Sci 18: 83.
33. Fienberg AA, Hiroi N, Mermelstein PG, Song W, Snyder GL, et al. (1998)
DARPP-32: regulator of the efficacy of dopaminergic neurotransmission.
Science 281: 838–842.
34. Greengard P, Allen PB, Nairn AC (1999) Beyond the dopamine receptor: the
DARPP-32/protein phosphatase-1 cascade. Neuron 23: 435–447.
35. Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, et al.
(2005) An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic
neurotransmission and behavior. Cell 122: 261–273.
36. Zhang L, Lou D, Jiao H, Zhang D, Wang X, et al. (2004) Cocaine-induced
intracellular signaling and gene expression are oppositely regulated by the
dopamine D1 and D3 receptors. J Neurosci 24: 3344–3354.
37. Valjent E, Corvol JC, Pages C, Besson MJ, Maldonado R, et al. (2000)
Involvement of the extracellular signal-regulated kinase cascade for cocaine-
rewarding properties. J Neurosci 20: 8701–8709.
38. Fukui R, Svenningsson P, Matsuishi T, Higashi H, Nairn AC, et al. (2003) Effect
of methylphenidate on dopamine/DARPP signalling in adult, but not young,
mice. J Neurochem 87: 1391–1401.
39. Valjent E, Pascoli V, Svenningsson P, Paul S, Enslen H, et al. (2005) Regulation
of a protein phosphatase cascade allows convergent dopamine and glutamate
signals to activate ERK in the striatum. Proc Natl Acad Sci U S A 102: 491–496.
40. Yan Z, Feng J, Fienberg AA, Greengard P (1999) D(2) dopamine receptors
induce mitogen-activated protein kinase and cAMP response element-binding
protein phosphorylation in neurons. Proc Natl Acad Sci U S A 96:
11607–11612.
41. Gerfen CR, Engber TM, Mahan LC, Susel Z, Chase TN, et al. (1990) D1 and
D2 dopamine receptor-regulated gene expression of striatonigral and striato-
pallidal neurons. Science 250: 1429–1432.
42. Pan D, Gatley SJ, Dewey SL, Chen R, Alexoff DA, et al. (1994) Binding of
bromine-substituted analogs of methylphenidate to monoamine transporters.
Eur J Pharmacol 264: 177–182.
43. Sanjuan MA, Pradet-Balade B, Jones DR, Martinez AC, Stone JC, et al. (2003)
T cell activation in vivo targets diacylglycerol kinase alpha to the membrane: a
novel mechanism for Ras attenuation. J Immunol 170: 2877–2883.
44. Topham MK, Prescott SM (2001) Diacylglycerol kinase zeta regulates Ras
activation by a novel mechanism. J Cell Biol 152: 1135–1143.
45. Regier DS, Higbee J, Lund KM, Sakane F, Prescott SM, et al. (2005)
Diacylglycerol kinase iota regulates Ras guanyl-releasing protein 3 and inhibits
Rap1 signaling. Proc Natl Acad Sci U S A 102: 7595–7600.
46. Yasuda S, Kai M, Imai S, Takeishi K, Taketomi A, et al. (2009) Diacylglycerol
kinase eta augments C-Raf activity and B-Raf/C-Raf heterodimerization. J Biol
Chem 284: 29559–29570.
Behavioral Phenotype of DGKß KO Mice
PLoS ONE | www.plosone.org 10 May 2012 | Volume 7 | Issue 5 | e37058